AngioGenex, Inc.

Pharmaceutical company · New York, United States

AngioGenex, Inc. is a pharmaceutical company headquartered in New York, United States. It has received 1 US government small-business research award (SBIR/STTR) from health agencies, $163,150 in total, most recently in 2010. It has reported private securities offerings to the US SEC, most recently $260,000 sold in a notice filed in 2021.

Profile compiled from public records. Is this your company? Request a correction or update

AngioGenex at a glance

Typepharmaceutical company
HeadquartersNew York, United States
SEC industryPharmaceutical Preparations
SEC CIK1085596

What does AngioGenex do?

US government research funding

1 SBIR/STTR small-business research award from US health agencies, $163,150 in total (2010).

Private fundraising reported to the SEC

2 Form D notices; the most recent reported $260,000 sold (2021).

Frequently asked questions about AngioGenex

Where is AngioGenex headquartered?

AngioGenex, Inc. is headquartered in New York, United States.

What does AngioGenex do?

AngioGenex, Inc. is a pharmaceutical company. Its SEC industry classification is Pharmaceutical Preparations.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Last updated 2026-09-25. Data licences